GH Research PLC (GHRS) Stock

GH Research PLC, a clinical-stage biopharmaceutical company, is dedicated to developing innovative therapies for psychiatric and neurological disorders. The company’s primary focus is on creating 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments for patients suffering from treatment-resistant depression (TRD). GH Research's flagship program, GH001, is an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a Phase 1/2 clinical trial in TRD patients.

In addition to GH001, GH Research PLC is advancing its pipeline with GH002, an injectable 5-MeO-DMT product candidate, and GH003, an intranasal 5-MeO-DMT product candidate. Both GH002 and GH003 are currently in preclinical development stages, with a focus on expanding treatment options for various psychiatric and neurological disorders. The company’s commitment to addressing unmet medical needs in mental health is underscored by its robust research and development efforts.

Incorporated in 2018 and headquartered in Dublin, Ireland, GH Research PLC combines scientific expertise with a patient-centric approach to pioneer new treatments in the biopharmaceutical field. By progressing its novel 5-MeO-DMT therapies through rigorous clinical trials, the company aims to offer transformative solutions for patients with challenging mental health conditions, positioning itself as a leader in the emerging field of psychedelic medicine.